spacer spacer spacer
> FAU PEOPLE DIRECTORY > SITE INDEX > ALTERNATIVE VIEW
spacer
spacer
spacer FAU WEB SEARCH spacer
spacer
Florida Atlantic University - Office of Technology Transfer
 
 

OTT Home Phys Sci & Eng
Life Sciences

Solid Tumor Cancer Therapy and Diagnostics

Bar

Description

Two highly cancer selective genes have been identified: Colon Carcinoma Related Gene (CCRG) that may provide a less invasive biomarker for colon cancer, and SIM2-s (C15) gene as a marker for colon, pancreas and prostate cancer.   CCRG is a secreted molecule and highly selective to colon cancers. Hence, detection of CCRG in serum can provide a basis for less invasive method of detection of colon cancers. In addition, the CCRG product can also be measured in the stool and hence can also capture the noninvasive market. Currently, the only secreted marker for cancer is PSA for prostate cancers. An antisense "drug" to the SIM2-s (C15) gene, has shown efficacy in killing cancer cells in pre-clinical and animal models, and has a novel mechanism with very low toxicity. The SIM2-s (C15) can also be useful as a surrogate marker for colon cancers.

Highly sensitive and specific diagnostic tests can be developed to detect DNA amplifications and/or the over-expression of new cancer specific genes at the RNA and protein level for first line diagnosis of disease.

Advantages

  • Antisense Smart Drug for SIM2-s
    • Lead drug that kills pancreas and colon tumors in place
    • Novel mechanism with low toxicity
    • Can be rapidly taken to the pancreatic cancer clinical trials
  • CCRG
    • Highly selective to colon cancers
    • Less invasive method of detecting colon cancers
    • CCRG can be measured noninvasively in stool
    • Can help predict drug response

Potential Applications

  • A Smart drug for pancreatic cancers and test kits based on CCRG and SIM2-s (C15) can be developed for treatment and early diagnosis of colon, pancreas and prostate cancers.
  • Diagnostic kits for colon, pancreas and prostate cancers

2000-01
The figure on the left shows that the SIM2-s gene marker is detectable at Benign Prostate Hyperplasia (BPH) prior to cancer development. The SIM2-s can potentially supplement PSA testing.


(c) Florida Atlantic University All rights reserved.
Updated August 2008

Inventor
Ramaswamy Narayanan, Ph.D.
Professor of Biological Sciences

IP Status
U.S. 6,780,642
Issued 8/24/2004

Canadian Patent Application
filed 8/6/2001

U.S. 6,677,119
Issued 1/13/2004

Contact Information
Office of Technology Transfer

Florida Atlantic University
777 Glades Road
Boca Raton, FL 33431-0991

Kurt R. Moore
Assistant V.P. & Director
Ph: 561-297-1165
Fax: 561-297-2141

kmoore34@fau.edu

Michelle Webb
Assistant Director
Ph: 561-297-0673
Fax: 561-297-2141
mwebb18@fau.edu

Case Number
2000-01, 2000-02

 
FAU Campuses: Boca Raton/Davie/Dania Beach/Fort Lauderdale/Jupiter/Treasure Coast Boca Raton Campus Danie Beach Campus Davie Campus Fort Lauderdale Campus Harbor Branch Campus Jupiter Campus Treasure Campus


 Privacy Policy | University Regulations and Policies | Emergency Information | Get Help at FAU | Contact Us

An Equal Opportunity/Equal Access Institution
© Copyright 2009. Florida Atlantic University

FAU Homepage